Gritstone to Present at the H.C. Wainwright Global Life Sciences Conference
March 02 2021 - 08:00AM
Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage
biotechnology company developing next generation cancer and
infectious disease immunotherapies, today announced that Andrew
Allen, M.D., Ph.D., co-founder, president and chief executive
officer, will present a company overview at the H.C. Wainwright
Global Life Sciences Conference which will be available on Tuesday,
March 9, 2021 at 7:00 a.m. ET.
A webcast will be available within the Investors & Media
section of the Gritstone website at
https://ir.gritstoneoncology.com/investors/events. An archived
replay will be accessible for 30 days following the event.
About Gritstone
OncologyGritstone Oncology (Nasdaq: GRTS), a
clinical-stage biotechnology company, is developing the next
generation of immunotherapies against multiple cancer types and
infectious diseases. Gritstone develops its products by leveraging
two key pillars—first, a proprietary machine learning-based
platform, Gritstone EDGETM, which is designed to predict antigens
that are presented on the surface of cells, such as tumor or
virally-infected cells, that can be seen by the immune system; and
second, the ability to develop and manufacture potent
immunotherapies utilizing these antigens to potentially drive the
patient’s immune system to specifically attack and destroy
disease-causing cells. The company’s lead oncology programs include
an individualized neoantigen-based immunotherapy, GRANITE, and an
“off the shelf” shared neoantigen-based immunotherapy, SLATE, which
are being evaluated in clinical studies. The company also has a
bispecific antibody (BiSAb) program for solid tumors in lead
optimization. Within its infectious disease pipeline, Gritstone is
advancing CORAL, a COVID-19 program to develop a second-generation
vaccine with support from departments within the National
Institutes of Health (NIH) and the Bill & Melinda Gates
Foundation and a license agreement with La Jolla Institute for
Immunology. Additionally, the company has a global collaboration
for the development of a therapeutic HIV vaccine with Gilead
Sciences. For more information, please visit
gritstoneoncology.com.
Gritstone ContactsMedia:Dan Budwick1AB(973)
271-6085dan@1abmedia.com
Investors:Alexandra Santos Wheelhouse Life Science Advisors(510)
871-6161asantos@wheelhouselsa.com
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Mar 2023 to Mar 2024